1-6 of 6
Deyaa Adib
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Interim Analysis of the Randomized Phase 1b/3 Study Evaluating the Safety and Efficacy of Tazemetostat Plus Lenalidomide and Rituximab in Patients with Relapsed/Refractory Follicular Lymphoma

Connie Lee Batlevi, Steven I. Park, Loretta Nastoupil, Tycel Phillips, Jennifer E. Amengual, David Andorsky, Philip Campbell, Pamela McKay, John M. Pagel, John P. Leonard, Jay Yang, Heather O'Connor, Anthony Hamlett, Deyaa Adib, Franck Morschhauser
Journal: Blood
Blood (2021) 138 (Supplement 1): 2207.
https://doi.org/10.1182/blood-2021-148199
Published: 2021
Journal Articles

Molecular and Genetic Characterization of Tumor Samples from Patients with Relapsed or Refractory Follicular Lymphoma Identifies Factors Influencing Response to Tazemetostat

Sandeep S. Dave, Lanie Happ, Christopher Yasso, Gilles Salles, Connie Lee Batlevi, Tycel Phillips, Jay Yang, Deyaa Adib, Neil R. Michaud, Franck Morschhauser
Journal: Blood
Blood (2021) 138 (Supplement 1): 1183.
https://doi.org/10.1182/blood-2021-151452
Published: 2021
Journal Articles

Tazemetostat Is Associated with Lower Risk for Safety Outcomes Versus the PI3-Kinases Idelalisib, Duvelisib and Copanlisib, in Patients with Relapsed/Refractory Follicular Lymphoma Who Have Received at Least 2 Prior Systemic Treatments: A Matching-Adjusted Indirect Comparison of Single-Arm Trials

David Proudman, MSc,MPH, Dave Nellesen, PhD, Deepshekhar Gupta, MS, Deyaa Adib, MD, Jay Yang, PhD, Michael Keith, PhD PharmD, Khalid Mamlouk, PharmD, BCOP
Journal: Blood
Blood (2020) 136 (Supplement 1): 16.
https://doi.org/10.1182/blood-2020-137772
Published: 2020
Journal Articles

Analyzing Efficacy Outcomes from the Phase 2 Study of Single-Agent Tazemetostat As Third-Line Therapy in Patients with Relapsed or Refractory Follicular Lymphoma to Identify Predictors of Response

Gilles Salles, MD PhD, Hervé Tilly, MD, Aristeidis Chaidos, MD PhD, Pam McKay, MD, Tycel J. Phillips, MD, Sarit E Assouline, MD MSc, Connie Lee Batlevi, MDPhD, Philip Campbell, MBBS, Vincent Ribrag, MD, Gandhi Laurent Damaj, MD PhD, Michael Dickinson, DMed Sci, Wojciech Jurczak, MD PhD, Maciej Kaźmierczak, MD PhD, Stephen Opat, FRACP, FRCPA, MBBS, John A. Radford, MD FMedSci, Anna Schmitt, MD, Jennifer Whalen, DHS, Anthony Hamlett, PhD, Beth Kamp, PharmD, Deyaa Adib, MD, Franck Morschhauser, MD PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 47–49.
https://doi.org/10.1182/blood-2020-137245
Published: 2020
Journal Articles

Phase 2 Multicenter Study of Tazemetostat, an EZH2 Inhibitor, in Patients with Relapsed or Refractory Follicular Lymphoma

Franck Morschhauser, MD PhD, Herve Tilly, MD PhD, Aristeidis Chaidos, Tycel J. Phillips, MD, Vincent Ribrag, MD, Philip Campbell, MBBS, FRACP, FRCPA, Damaj Gandhi Laurent, MD PhD, Wojciech Jurczak, MD PhD, Pamela McKay, MD, Stephen Opat, John Radford, Jennifer Whalen, Anand Rajarethinam, Susan Benedict Navia, Deyaa Adib, Gilles Salles, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 123.
https://doi.org/10.1182/blood-2019-128096
Published: 2019
Journal Articles

Interim Results from an Ongoing Phase 2 Multicenter Study of Tazemetostat, an EZH2 Inhibitor, in Patients with Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)

Vincent Ribrag, Franck Morschhauser, Pamela McKay, MD, Gilles Andre Salles, Connie Lee Batlevi, MD, Anna Schmitt, Herve Tilly, MD, Guillaume Cartron, Catherine Thieblemont, MD, Christophe Fruchart, John G. Gribben, Thierry Lamy, Steven Le Gouill, Reda Bouabdallah, MD, Michael Dickinson, MD, Stephen Opat, Deyaa Adib, Stephen J Blakemore, John Larus, Peter Johnson, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 4196.
https://doi.org/10.1182/blood-2018-99-113411
Published: 2018